Mucosal-associated invariant T (MAIT) cells are conserved T cells that express a semi-invariant T-cell receptor (Va7.2 in humans and Va19 in mice). The development of MAIT cells requires the antigen-presenting MHC-related protein 1 (MR1), as well as commensal bacteria. The mechanisms that regulate the functional expression of MR1 molecules and their loading with bacterial antigen in antigen-presenting cells are largely unknown. We have found that treating B cells with the Toll-like receptor 9 (TLR9) agonist CpG increases MR1 surface expression. Interestingly, activation of TLR9 by CpG-A (but not CpG-B) enhances MR1 surface expression. This is limited to B cells and not other types of cells such as monocytes, T or natural killer cells. Knocking-down TLR9 expression by short hairpin RNA reduces MR1 surface expression and MR1-mediated bacterial antigen presentation. CpG-A triggers early endosomal TLR9 activation, whereas CpG-B is responsible for late endosomal/lysosomal activation of TLR9. Consistently, blocking endoplasmic reticulum to Golgi protein transport, rather than lysosomal acidification, suppressed MR1 antigen presentation. Overall, our results indicate that early endosomal TLR9 activation is important for MR1-mediated bacterial antigen presentation.
Introduction
Mucosal-associated invariant T (MAIT) cells are conserved T cells that express a semi-invariant T-cell receptor (Va7.2 in humans and Va19 in mice). The development of MAIT cells requires the antigen-presenting MHC class I-related protein 1 (MR1), as well as commensal bacteria, because germ-free or MR1-deficient animals do not develop MAIT cells. 1 Human MAIT cells are abundant in the gut lamina propria, lung and liver. 1 Similar to another subpopulation of innate T cells, CD1d-restricted natural killer T (NKT) cells, MAIT cells have the capacity to bridge innate and adaptive immunity. MAIT cells can respond to bacteria-infected antigen-presenting cells (APCs) and rapidly secrete pro-inflammatory cytokines such as interferon-c and tumour necrosis factor-a, as well as Granzymes A and B. 1 The most studied and only known function of MAIT cells is their anti-microbial activity. 2, 3 Reduced MAIT cell levels have been reported in different pathological conditions, such as obesity, bacterial and viral infections, as well as autoimmune diseases. [4] [5] [6] [7] [8] [9] [10] In addition to MAIT cell development, MR1 is also required for MAIT cell activation. 11, 12 It was recently discovered that bacterial vitamin B-derived metabolites are antigens for MAIT cells. 13, 14 B cells were the first identified (and are the most prominent) APCs for MAIT cells, 11 although other cell types, such as thymocytes, monocytes and epithelial cells, can also activate MAIT cells. [15] [16] [17] MR1 is ubiquitously expressed, but is mostly localized in the cytosol. Hence, B cells normally express few MR1 molecules on the cell surface; however, upon a bacterial infection, MR1 translocates to the cell surface with loaded antigen and activates MAIT cells by interacting with the invariant T-cell receptor. 12, 18 Toll-like receptors (TLRs), a type of pattern-recognition receptors, are germline-encoded proteins that recognize conserved molecules of foreign pathogens, also called pathogen-associated molecular patterns (PAMPs). TLRs are essential for host defence against infections. 19 For example, upon a bacterial infection, TLR-expressing cells can recognize the bacterial PAMPs and lead to the secretion of Type I interferon, tumour necrosis factor-a, interleukin-12 (IL-12) and other cytokines. 20 In addition, the activation of TLRs can modify endogenous lipid antigen synthesis in APCs and impact CD1d-mediated antigen presentation to NKT cells. 21, 22 However, MAIT cell activation is different from that of NKT cells, in that it requires antigens such as microbial vitamin Bderived metabolites. 13 The role of TLRs in MR1-mediated bacterial antigen presentation to MAIT cells has not been extensively studied. With B cells being essential for MAIT cell development in the periphery, 11 in the current study, we explored the role of TLRs in regulating MR1-mediated bacterial antigen presentation in B cells.
Materials and methods

Cells and reagents
An Epstein-Barr virus-transformed human B lymphoblastoid cell line (B-LCL) from de-identified donated human blood was generated (and kindly provided) by Dr Janice Blum (Indiana University, Indianapolis, IN). THP-1, a human monocytic leukaemia cell line, was a kind gift from Dr Louis Pelus (Indiana University, Indianapolis, IN). A panel of lentiviral short hairpin RNAs (shRNA) targeting TLR9 (Sigma-Aldrich, St Louis, MO) were used to generate individual lines of TLR9-deficient B-LCL cells. To generate MAIT cells, human peripheral blood mononuclear cells (PBMCs) were isolated from de-identified buffy-coats from healthy blood donors (Indiana Blood Center, Indianapolis, IN) by density-gradient centrifugation using Ficoll-Hypaque (GE Healthcare, Piscataway, NJ). Va7.2 + CD161 + T (MAIT) cells were sorted by flow cytometry. MAIT cells were expanded by stimulation with irradiated allogeneic human PBMCs in the presence of paraformaldehyde-fixed Escherichia coli [DH5a, multiplicity of infection (MOI) = 300] and recombinant human IL-2 (10 ng/ml; Peprotech, Rocky Hill, NJ). The enrichment and expansion of MAIT cells after 21 days in culture are shown in the Supplementary material (Fig. S1 ). All cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 lg/ml streptomycin. A human TLR1-TLR9 agonist kit containing stock solutions of Pam3CSK4 (TLR1/2, 100 lg/ml), HKLM (TLR2, 10 10 cells/ml), Poly(I : C)-HMW (TLR3, 1 mg/ ml), LPS (TLR4, 100 lg/ml), Flagellin (TLR5, 100 lg/ ml), FSL1 (TLR6/2, 100 lg/ml), Imiquimod (TLR7, 100 lg/ml), ssRNA40 (TLR8, 100 lg/ml) and ODN2006 (TLR9, 500 lM), was purchased from InvivoGen (San Diego, CA). Unmethylated CpG oligodeoxynucleotides ODN2216 (CpG-A, 500 lM), ODN2006 (CpG-B, 500 lM), ODN TTAGGG (TLR9 antagonist, 500 lM) and controls were also purchased from InvivoGen. 6-Formylpterin was purchased from Cayman Chemical Co. (Ann Arbor, MI). Conditioned medium is medium from CpGtreated B-LCL cells and was concentrated using an ultra-centrifugal filter (molecular weight 10 000 cut-off; Millipore, Billerica, MA). Phycoerythrin/Cy7-conjugated anti-human CD19, BD Horizon TM V450-conjugated antihuman CD16, AlexaFluor700-conjugated anti-human CD14, AlexaFluor488-conjugated anti-human CD3, Brefeldin A and Monesin were purchased from BD Biosciences (San Jose, CA). Chloroquine and bafilomycin A1 were from Sigma-Aldrich.
Flow cytometry
B-LCL cells were treated with paraformaldehyde-fixed E. coli (MOI = 300) or the TLR9 agonist CpG (5 lM) overnight as indicated, followed by staining with an allophycocyanin-conjugated anti-MR1 monoclonal antibody (Clone 26.5; Biolegend, San Diego, CA). For total MR1 staining, cells were fixed with paraformaldehyde and permeabilized with 0Á1% saponin. Cells were then stained with allophycocyanin-conjugated anti-MR1. For human PBMCs, cells were treated with fixed E. coli (MOI = 300) or TLR9 agonists overnight. The cells were stained with PE/Cy7-conjugated anti-CD19, BD Horizon TM V450-conjugated anti-CD16, AlexaFluor700-conjugated anti-CD14, AlexaFluor488-conjugated anti-CD3 and allophycocyaninconjugated anti-MR1 antibodies. The cells were analysed by flow cytometry as previously described. 23 
Western blotting
Cell lysates were analysed by immunoblotting as described previously.
24 TLR9, tumour-necrosis factorreceptor-associated factor 3 (TRAF3) and interferon regulatory factor 7 (IRF7) -specific antibodies (Cell Signaling Technology, Danvers, MA) were used to detect TLR9, TRAF3 and IRF7 expression, respectively. The membrane was stripped and re-probed with a GAPDH-specific antibody (Cell Signaling Technology) as a control for sample loading. Protein expression was quantified using IMAGEJ software (1Á46v; National Institutes of Health, Bethesda, MD).
MAIT cell activation assay
B-LCL cells were co-cultured with MAIT cells in the presence of fixed E. coli (MOI = 300) or CpG-A (5 lM) for 72 hr. For drug treatments, B-LCL cells were treated with the specific inhibitors as indicated, in the presence of fixed E. coli overnight. The cells were then washed, fixed and co-cultured with MAIT cells for 72 hr. For shRNAexpressing B-LCL cells, the cells were treated with fixed E. coli overnight. The cells were then fixed and cocultured with MAIT cells as described above. MAIT cell activation was measured by interferon-c production into the supernatants and detected by ELISA.
Statistical analysis
Graphs were generated and analysed by an unpaired twotailed Student's t-test or one-way analysis of varaince using PRISM software (version 6.05 for Windows; GraphPad, San Diego, CA). The error bars in the bar graphs show the standard deviation (SD) from the mean. A P-value < 0Á05 was considered significant.
Results
TLR9 activation increases MR1 surface expression in B cells
Previous work has shown that a bacterial infection of B cells increases MR1 surface expression. 12 Because bacteria contain many PAMPs that may activate host immune cells, we assessed whether the activation of TLRs is responsible for this up-regulation of MR1 surface expression. We observed that only the TLR9 agonist ODN 2216 at high concentrations (i.e. 1 : 100; 5 lM) profoundly increased MR1 surface expression on B-LCL cells (Fig. 1a,  b) . The up-regulation of surface MR1 was even higher when B-LCL cells were treated with a 50 lM of ODN 2216 (data not shown), suggesting a dose-dependent response. This MR1 up-regulation by ODN 2216 was similar to that induced by bacteria (Fig. 1b) . Our data suggest that TLR9 activation increases MR1 surface expression in B cells. Although fixed E. coli or CpG treatment increased surface MR1, total MR1 levels were not altered (Fig. 1c,d ). This observation suggests that TLR9 activation promotes the intracellular translocation of MR1 to the cell surface. In line with this idea, the up-regulation of MR1 surface expression by CpG ODN2216 was blocked by a TLR9 antagonist (ODN TTAGGG), but not by control ODN (Fig. 1e ). These data demonstrate TLR9 specificity in the induction of MR1 cell surface expression. In addition, when treated with CpG ODN2216 or fixed E. coli, primary CD19 + B cells from human blood also showed increased MR1 surface expression (Fig. 1f) . Altogether, these results suggest that the activation of TLR9 enhances MR1 surface expression in B cells.
CpG-A (but not CpG-B) induces MR1 surface expression in B cells
Unlike CpG ODN2216, another TLR9 CpG agonist, ODN2006, did not induce MR1 surface expression in B-LCL cells (Fig. 1a) . CpG DNA is categorized into three major classes based on structure and sequence motif: A, B and C. 25 Class A CpG (CpG-A) contains a central palindromic phosphodiester CpG sequence and a phosphorothioate-modified 3 0 poly-G tail. CpG-A is better at activating NK and plasmacytoid dendritic cells (pDCs), but is a poor activator of B cells. 25 Class B CpG (CpG-B) has a nuclease-resistant phosphorothioate backbone and is better at stimulating B cells. Class C CpG is a combination of Class A and B. 25 Interestingly, we found that ODN2216 (CpG-A), but not ODN2006 (CpG-B), increased MR1 surface expression in B-LCL cells (Fig. 2a) or primary B cells (Fig. 2b,c) . Both CpG-A and CpG-B stimulated IL-6 production from human PBMCs (see Supplementary material, Fig. S2 ), confirming the bioactivity of both reagents. Therefore, we conclude that CpG-A, although better known as an activator of NK and pDCs, also increases MR1 surface expression on B cells.
TLR9 agonists have different effects on MR1 surface expression in other cell types
To determine how TLR9 activation impacts MR1 expression in other cell types, we treated human PBMCs with CpG-A, CpG-B and fixed E. coli. We found that neither CpG-A nor CpG-B enhanced MR1 surface expression on T (CD3 + ) cells, although adding fixed E. coli did (Fig. 3a) . Although CpG-A at a high concentration (5 lM) significantly enhanced MR1 surface expression on NK (CD16 + ) cells, the increase was less than 1Á5-fold ( Fig. 3b ; bar graph). CpG-B treatment caused no change in MR1 surface expression on NK cells (Fig. 3b) . Interestingly, on the other hand, both CpG-A and CpG-B increased MR1 surface expression on monocytes (CD14 + ) in a dose-dependent manner (Fig. 3c ). To further test the effect of CpG-A and CpG-B on MR1 surface expression in monocytes, we used the monocytic cell line, THP-1. THP-1 cells express a higher level of surface MR1 compared with monocytes derived from PBMCs (Fig. 3d) . We found that TLR4 and TLR5 agonists increased MR1 surface expression on THP-1 cells (Fig. 3f) . In contrast, although CpG-A and CpG-B increased MR1 surface expression on monocytes, they both reduced MR1 surface expression in THP-1 cells (Fig. 3e ). These data suggest that THP-1 cells are different from primary monocytes in responding to activation by TLR9 agonists. However, it is important to mention that treatment with fixed E. coli enhanced MR1 surface expression in B cells, THP-1 cells and all other PBMC-derived blood cells we tested (Figs 1b,f and 3a-c,e). These results demonstrate that MFI of surface MR1 
TLR9 is required for MR1 surface expression in B-LCL cells
It was previously reported that B cells are essential for MAIT cell development in the periphery. 11 Hence, we focused our study on B cells. To confirm that TLR9 is necessary for MR1 surface expression in B cells, we used an shRNA approach to specifically knock down TLR9 expression in B-LCL cells. Reduced TLR9 expression was verified by Western blot analysis (Fig. 4a,b) . When these TLR9 shRNA cells were treated with fixed E. coli or CpG-A, reduced surface MR1 was observed in these cells compared with cells expressing scrambled shRNA (NC; Fig. 4c-e) . It is well-known that B-LCL cells produce many cytokines and chemokines upon activation. 26 To determine whether any soluble factors from CpGactivated B-LCL cells, rather than TLR9 activation itself, up-regulate MR1 surface expression, B-LCL cells were cultured in conditioned medium from CpG-treated B-LCL cells. We found that conditioned medium did not rescue reduced MR1 surface expression in TLR9-deficient cells (Fig. 4f ). These results demonstrate that TLR9 is directly responsible for the up-regulation of MR1 surface expression.
Reduced bacterial antigen presentation in TLR9-deficient B cells
It has been previously shown that bacterial antigens are essential for MR1-mediated stimulation of MAIT cells. (Fig. 5a ). These results confirm the necessity of a bacteria-derived antigen for MAIT cell activation. 13 To determine the role for TLR9 in MR1-mediated bacterial antigen presentation, B-LCL cells in which TLR9 was knocked down by shRNA were used as APCs. There are several factors other than antigen presentation that may impact MAIT cell activation, such as different growth rates in APCs or cytokines (i.e. IL-12 and IL-18) from activated APCs. To eliminate these potential factors, APCs were fixed in paraformaldehyde after being treated with fixed E. coli overnight, and then co-cultured with MAIT cells. We found that B-LCL cells in which TLR9 was knocked down were significantly impaired in their ability to stimulate MAIT cells (Fig. 5b and see Supplementary material, Fig. S3 ). Therefore, we conclude that TLR9 is important for MR1-mediated antigen presentation.
Early endosomal signalling of TLR9 by CpG-A enhances MR1 surface expression and antigen presentation
Previous studies have demonstrated that CpG-A and CpG-B induce distinct TLR9 downstream signalling pathways in pDCs. 27 CpG-A is less stable and usually aggregates and interacts with TLR9 in early endosomes. 28 This interaction triggers the activation of MyD88 and other downstream mediators, such as TRAF3, IRF7 and type I interferon production. 27 In contrast, CpG-B is more stable and transported to late endosomes/lysosomes, which results in the activation of different downstream signalling molecules in the TLR9 signalling pathway, such as nuclear factor-jB and mitogen-activated protein kinase; this leads to pro-inflammatory cytokine production. 27 Because CpG-A (but not CpG-B) increased MR1 surface expression in B cells (Fig. 2) , we hypothesized that early endosomal signalling of the TLR9 pathway by CpG-A is important for the observed increase in MR1 surface expression. To test this hypothesis, TRAF3 and IRF7, two downstream mediators of the early endosomal TLR9 signalling pathway induced by CpG-A, 27 were knocked-down in B-LCL cells using lentiviral shRNA (Fig. 6a,b) . These results provide further strong support that early endosomal TLR9 signalling is important for MR1 surface expression.
Importantly, blocking lysosomal function with the lysosomal inhibitors bafilomycin and chloroquine, had little impact on MR1 surface expression (Fig. 6c) or MR1-mediated antigen presentation (Fig. 6d) . This is consistent with our observation that CpG-B, which signals through late endosomes/lysosomes, 27 does not enhance MR1 surface expression in B cells. In contrast, the Golgi inhibitors brefeldin A and monensin, impaired both MR1 surface expression and MR1-mediated antigen presentation ( Fig. 6c,e; see Supplementary material, Fig. S5 ). All of these pharmacological inhibitors were used at concentrations that exhibited little effect on cell viability (data not shown). Overall, these data support the importance of early endosomes, but not late endosomes or lysosomes, in bacterial antigen presentation by MR1. Therefore, we conclude that early endosomal signalling of TLR9 by CpG-A enhances MR1 surface expression and antigen presentation.
Discussion
In the current study, we demonstrate that activation of TLR9 regulates MR1 surface expression and bacterial antigen presentation in B cells (Fig. 7) . It has been previously shown that the activation of TLRs in APCs enhances MAIT cell activation in a T-cell receptor-independent manner. The Lantz group has shown that bone-marrow-derived DCs from MyD88 knockout mice are less able to activate MAIT cells, 2 suggesting that TLRs are likely to be important for MR1-mediated antigen presentation. Our data suggest that bacteria not only provide bacterial antigens, but also PAMPs that activate MAIT cells. Indeed, Chen et al., 30 have demonstrated that co-stimulatory signals, such as TLR ligands, are as essential as microbial antigen in MAIT cell activation and accumulation in vivo. It has been demonstrated by several laboratories that endocytic trafficking is important for MR1-mediated antigen presentation. 12, [31] [32] [33] To the best of our knowledge, our study is the first to directly show that the early endosomal TLR9 signalling pathway is important for antigen presentation by MR1. Consistent with our data, two groups have recently shown that brefeldin A suppressed the functional expression of MR1 in their individual experimental systems. 32, 33 The SNARE proteins Stx18 and VAMP4, as well as the small GTPase Rab6, were identified as important regulators of MR1-dependent antigen presentation. 33 Future investigations will focus on how TLR9 signalling influences the function of SNARE proteins and intracellular trafficking of MR1.
Our finding that the TLR9 agonist CpG-A enhances MR1 surface expression was a surprise, because CpG-A is not considered a potent activator of B cells. It is wellknown that CpG-A is a strong activator of pDCs and NK cells, whereas CpG-B activates B cells. 25 CpG-A has been shown to induce a modest response in B cells, but only at a high concentration. 34 This is consistent with our observation that CpG-A induces the up-regulation of MR1 at high concentrations (e.g. 5 lM; Fig. 1 ). The fact that CpG-A stimulates B cells only at much higher concentrations, compared with CpG-B, is probably due to the instability of CpG-A and a paucity of CpG-A-binding cell surface receptors (e.g. CXCL16) on B cells. 34, 35 On the other hand, previous studies have suggested that high concentrations of CpG-B inhibit B-cell activation. 36 We also observed reduced IL-6 production from PBMCs when stimulated with high concentrations of CpG-B (see Supplementary material, Fig. S2 ). However, at none of the concentrations we tested, was CpG-B able to induce MR1 surface expression (Fig. 3c) . Therefore, our data suggest that CpG-A can activate B cells at high concentrations and its function is different from that of CpG-B.
We found that TLR9 activation increases MR1 surface expression in some types of cells (e.g. monocytes and B cells) but has a minimal impact in others (e.g. T and NK cells). TLR4 and TLR5 agonists enhance MR1 surface expression in THP-1, but not B-LCL cells (Figs 1a and 3f ). This may be explained by differential expression of TLRs in these cells. Ussher et al., 31 reported that activation of several TLRs by TLR-specific agonists enhances MR1-mediated antigen presentation. They also found almost no increase in surface MR1 expression after treatment with fixed E. coli in B-LCL or THP-1 cells. They also showed low baseline MR1 surface expression in THP-1 cells. 31 The differences in MR1 surface expression between our two studies may simply be due to the MR1-specific reagents used. For example, Ussher et al., used an anti-MR1 antibody conjugated with AlexaFluor488, a weaker fluorochrome compared with allophycocyanin, which is what we used; this would impact the level of detectable MR1 on cell surface by flow cytometry. Additionally, others have reported that a bacterial infection of B cells increases MR1 surface expression. 12 McWilliam et al. 32 have recently shown that MR1 molecules are localized in the endoplasmic reticulum at steady state and traffic to the plasma membrane; however, this only occurs after being loaded with bacterial antigen. Our studies suggest a different mechanism for MR1 surface expression in the absence of a bacterial antigen. This TLR9-dependent up-regulation of MR1 is likely to be MAIT cell activation was measured by interferon-c production into the supernatants. Each bar is the mean of triplicate samples AESD. *P < 0Á05; **P < 0Á01. **** P < 0Á0001 The data are representative of at least three independent experiments. different from bacterial antigen-mediated MR1 surface expression, because we only observed MR1 up-regulation in B cells and monocytes (Figs 1 and 3c) . The bacteriainduced MR1 up-regulation is common among all cells analysed to date. 32 Interestingly, treatment of fixed E. coli increases MR1 surface expression in almost all cell types we tested (Figs 1 and 3 and data not shown) . Thus, the increase of MR1 surface expression by fixed E. coli may be due to it being loaded with bacterial antigens, rather than by the activation of TLRs. It will be interesting to determine whether these two different surface expression mechanisms influence each other in bacterially infected APCs.
We have demonstrated that the TLR9 agonist CpG-A increases MR1 surface expression in B cells. Reduced MR1 surface expression in TLR9-deficient B-LCL cells further confirmed the importance of TLR9 signalling in regulating MR1 function (Fig. 4) . In fixed E. coli-treated TLR9-deficient B-LCL cells, although there was a significantly reduced ability to activate MAIT cells, they could still stimulate a very high level of interferon-c production by MAIT cells (Fig. 5b) . One may question whether other factors, such as IL-12 and IL-18 from APCs, contributed to the MAIT cell activation in this case. This is highly unlikely, because the APCs were fixed and would not be expected to produce any cytokines. The observed MAIT cell activation might be due to the presence of other intact TLRs in B cells, although activation of these TLRs does not increase MR1 surface expression. An alternative explanation could be that the residual TLR9 in shRNA cells was sufficient to stimulate MR1-mediated antigen presentation at a high level. It is worthwhile to point out that adding pure bacterial antigens to APC/MAIT cell co-cultures can stimulate MAIT cell activation.
14 This suggests that TLR activation is not required for MR1-mediated bacterial antigen presentation; rather, we think it helps facilitate this response.
Even if MR1 is present at low levels on the cell surface, if antigen is available in excess, it would be very likely sufficient for the activation of MAIT cells. 14, 37 However, it could also be argued that high levels of antigen-loaded MR1 might 'mask' the importance of TLR activation in the regulation of MR1-mediated bacterial antigen presentation. In support of this idea, Ussher et al. 31 showed that, although MAIT cells incubated with THP-1 or B-LCL cells in the presence of E. coli culture supernatants showed little activation, when MR1-overexpressing APCs were used, MAIT cell stimulation was significantly enhanced. In contrast, in the presence of intact E.coli, APCs with or without MR1 overexpression comparably stimulated MAIT cell activation. Their work suggests the importance of TLR activation when MR1 expression is low. Therefore, we speculate that primary signalling from antigen-loaded MR1 is essential for MAIT cell activation. That being said, secondary signalling from TLRs is also important in enhancing MAIT cell activation, especially when MR1 and/or bacterial antigens are at relatively lower levels.
The potential of bacterial DNA to activate TLR9 is dependent on the individual dinucleotide [CG] content. 38 Interestingly, those bacterial species that are more able to stimulate TLR9, such as Psuedomonas aeruginosa or Klebsiella pneumoniae, activate MAIT cells at low MOI (MOI = 1-10). On the other hand, a few other bacterial strains, including Staphylococcus aureus and Staphylococcus epidermidis, have a minimal ability to activate cells via TLR9. Hence, they activate MAIT at an MOI of 100 or above. 2, 38 This is consistent with our data showing that TLR9 is important for MAIT cell activation. Enterococcus faecalis is also a poor activator of MAIT cells, probably because it lacks the bacterial antigen riboflavin synthesis genes. 39 Interestingly, Enterococcus faecalis also lacks the ability to activate TLR9. 2, 38 When mixed with E. coli supernatants that contain bacterial antigens, Enterococcus faecalis still cannot induce an efficient MAIT cell response. 31 The importance of TLR9 activation in MR1-mediated antigen presentation may provide an alternative explanation for the inability of Enterococcus faecalis to activate MAIT cells, even in the presence of bacterial antigen. Our work supports the hypothesis that certain bacterial species in the gut microbiota favour MAIT cell function, because they not only provide bacterial antigens, but also activate TLR pathways that enhance MAIT cell activation. A recent study has found that TLR agonists (including CpG) provide the necessary co-stimulatory function to drive MAIT cell accumulation when administered in vivo, together with a synthetic MR1 antigen. 30 Hence, we conclude that TLR9 is critical for MR1-mediated bacterial antigen presentation.
MAIT cells have the ability to clear bacterial infections. 40 B cells are required for MAIT cell expansion in the periphery. 41 Our data suggest that TLR9 regulates MR1-mediated bacterial antigen presentation in B cells. This further supports the importance of B cells in MAIT cell development and host immune response to bacterial infections. Indeed, patients with a B-cell deficiency, such as X-linked agammaglobulinaemia, do experience recurrent infections. 42 This would certainly be consistent with these patients lacking MAIT cells, as patients with X-linked lymphoproliferative syndrome do have low numbers of MAIT (and NKT) cells. 43 Our study indicates a unique function of B cells in sensing bacterial PAMPs and activating MAIT cells.
In conclusion, we have shown that TLR9 activation is essential for MR1-mediated bacterial antigen presentation and it does so by regulating MR1 intracellular trafficking (summarized in Fig. 7) . Future work will focus on how the TLR9 signalling pathway regulates the endocytic trafficking of MR1 and bacterial antigen processing/presentation. Our studies provide insightful information for potentially developing CpG-A as an adjuvant for MAIT cell-based immunotherapy.
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